Predemtec GmbH
"The test developed with the help of ILB and HTGF support enables the determination of Alzheimer's disease with a specificity and sensitivity of more than 90 percent through the immunological determination of six biomarkers in blood. The test also enables differential diagnosis of vascular dementia."
Dr. Patrick Scotten, Co-founder, Predemtec GmbH
| Company details | |
| Name/legal form | Predemtec GmbH |
| Sector | Biotechnology |
| Business | Research, development and marketing of platforms for dementia diagnostics and research into new types of treatment for dementia |
| Founding team | Dr. Annegret Feuerhelm-Heidl, Prof. Dr. Asmus Finzen, Dr. Patrick Scotten |
| Established | 15 August 2011 |
| CEO(s) | Dr. Annegret Feuerhelm-Heid |
| Support details | |
| Project | Development of an in-vitro test for early diagnosis of Alzheimer's disease and other forms of dementia |
| Support programmes | GRW-G, Gründung innovativ, Innovationsgutschein |
| Year | 2013, 2014, 2015 |
Contact:Predemtec GmbHNeuendorfstraße 18a, 16761 Hennigsdorf bei BerlinContact: Dr. Annegret Feuerhelm-HeidlTelephone: +49 (0)3302 559 170E-Mail: info@predemtecdx.comwww.predemtecdx.com(öffnet externe Seite)
Petra QuehlCommunication/ Start-up InitiativesProject CoordinatorTel.: 0331 660-1799Fax.: 0331 660-61799E-Mail Kontakt